← Evidence library

BIB_328

Robert C et al. (Gustave Roussy + Paris-Saclay + multicentre). KEYNOTE-006 10-year follow-up: pembrolizumab vs ipilimumab in stage IV melanoma. ESMO 2024-2025. Key numbers: 10-year MSS 45.2% pembro vs 31.3% ipi. 10-year OS 36% pembro vs 27% ipi. Defines the cure fraction of modern Stage IV melanoma immunotherapy. [Tasks: 18, 19b, 22, 23, 25] Tier: 1 (ESMO + JCO) Grade: A Retrieved: 2026-05-15

Evidence grade

A

Tier

1 (ESMO + JCO)

Cited by tasks

18, 19b, 22, 23, 25

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_328/findings.md (research corpus). This page is a short context summary — not individualised medical advice.